Chapter Thirteen - EBV, the Human Host, and the 7TM Receptors: Defense or Offense?
Section snippets
EBV Infection
Epstein–Barr virus (EBV, human herpesvirus 4) was discovered 50 years ago, when Epstein, Achong, and Barr used electron microscopy to identify viral particles in Burkitt's lymphoma cells.1 It belongs to the lymphocryptovirus (LCV) genus of the gammaherpesvirus subfamily2 (Fig. 1A). The EBV genome, which consists of a linear, double-stranded DNA molecule that encodes close to 100 viral genes, is enclosed in a nuclear capsid surrounded by a protein tegument, which in turn, is surrounded by a
Immune Response and Immune Evasion
Up to 10% of the host B cells are infected with EBV during acute infectious mononucleosis.43 Most of these cells are effectively cleared by the immune system, but some downregulate viral gene expression and differentiate into safety in the resting memory B cell pool. In the persisting infection, the virus and host coexist, so that homeostasis of the infected memory B cell pool is maintained by continuous low-level virus shedding while the immune system ensures that no full blown lytic
EBV-BILF1—A Virus-Encoded 7TM Receptor with Immune Evasive Functions
The EBV-encoded BILF1 receptor (EBV-BILF1) is thought to be implicated in the immune evasion strategy of EBV.56, 61, 62 This orphan 7TM receptor is expressed at significant levels during the early lytic phase of the virus infection, intermediate levels in LCLs and nasopharyngeal carcinoma derived C666-1 line and at low levels during the viral latent phase.63, 64 Several studies have shown that the pivotal role in immune evasion played by EBV-BILF1 occurs during the lytic replication rather than
EBI2: An Endogenous 7TM Receptor Manipulated by EBV
EBI2 was identified in 1993, when Kieff and colleagues used subtractive hybridization of DNA from Burkitt's lymphoma cells to screen for upregulated genes in EBV-infected cells.87 They found, being more than 200-fold upregulated (hence the name: EBV-induced gene 2). Since 1993, this finding has been confirmed in four different studies describing EBI2 upregulation in both lytic and latent settings29, 88, 89, 90 (see Table 2).
The name of EBI2 suggests that EBV directly induces expression of the
Manipulation of the Host Immune System 7TM Receptors and Ligands by EBV—The Chemokine System
Chemokines induce chemotaxis of leukocytes through interactions with 7TM chemokine receptors. Approximately, 40 chemokines and 18 functional chemokine receptors have been identified in humans. Based on the pattern of conserved cysteine residues in the N-terminal region they are classified into four subfamilies: CC, CXC, C, and CX3C.119 By controlling leukocyte migration, the chemokine system has important functions in coordinating the immune system, leukocyte homeostasis, lymphocyte activation,
EBV-Associated Diseases
Primary EBV infection often occurs in young immunocompetent children and is asymptomatic or present with nonspecific mild symptoms.6 However, given that EBV was originally identified in Burkitt's lymphoma cells and has the unique ability to transform resting B cells into highly proliferating lymphoblasts, it is not surprising that this virus is associated with a number of cancers in both immunocompromised and immunocompetent patients. In addition, EBV has been associated with autoimmune
Drug-Target Potential
7TM receptors and in particular class A receptors to which the 7TM receptors mentioned in this review belong, are highly druggable molecules. Approximately, 35% of all currently marketed drugs target class A 7TM receptors.157 There is no specific antiviral treatment for EBV. Current treatment strategies for EBV-associated lymphomas include B cell antibodies (rituximab, chimeric, and monoclonal antibody against CD20), reducing immunosuppression, EBV-specific CTL infusion, and chemotherapy for
Conclusions
In summary, EBV encodes one 7TM receptor and manipulates endogenous 7TM receptors, some of which are involved in the virus life cycle and some of which may be involved in the antiviral host defense. In the case of EBI2, we are still unclear on whether the upregulation is virus mediated or immune system mediated. Nevertheless, EBI2 is upregulated in EBV-associated PTLD and, together with BILF1 and the chemokine receptors constitute potential drug targets in EBV-mediated diseases. Further studies
Acknowledgment
The authors thank Nick Davis-Poynter and Katja Spiess for critical reading of this manuscript and for helpful comments.
References (159)
- et al.
Virus particles in cultured lymphoblasts from Burkitt's lymphoma
Lancet
(1964) - et al.
Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis
Cell
(1987) - et al.
Characterization of the Epstein-Barr virus glycoprotein BMRF-2
Virology
(2007) - et al.
Efficiency of transformation of lymphocytes by Epstein-Barr virus
Virology
(1977) - et al.
An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells
Cell Host Microbe
(2010) - et al.
Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals
Immunity
(1998) - et al.
The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell
Immunity
(2000) - et al.
The pathogenesis of Epstein-Barr virus persistent infection
Curr Opin Virol
(2013) - et al.
EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency
Immunity
(2000) - et al.
Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue
Blood
(1992)
Epstein-Barr virus and host cell methylation: regulation of latency, replication and virus reactivation
Curr Opin Virol
CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease
Blood
Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice
Blood
Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection
Cell Rep
Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10
Blood
Discerning regulation of cis- and trans-presentation of CD8 + T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation
Blood
Selective elimination of high constitutive activity or chemokine binding in the human herpesvirus 8 encoded seven transmembrane oncogene ORF74
J Biol Chem
The carboxyl terminus of human cytomegalovirus-encoded 7 transmembrane receptor US28 camouflages agonism by mediating constitutive endocytosis
J Biol Chem
Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28
J Biol Chem
Similar activation of signal transduction pathways by the herpesvirus-encoded chemokine receptors US28 and ORF74
Virology
Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74
J Biol Chem
The CXC chemokine receptor encoded by herpesvirus saimiri, ECRF3, shows ligand-regulated signaling through Gi, Gq, and G12/13 proteins but constitutive signaling only through Gi and G12/13 proteins
J Biol Chem
Molecular piracy of mammalian interleukin-8 receptor type B by herpesvirus saimiri
J Biol Chem
Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28
FEBS Lett
Molecular pharmacological phenotyping of EBI2. An orphan seven-transmembrane receptor with constitutive activity
J Biol Chem
Molecular characterization of oxysterol binding to the Epstein-Barr virus-induced gene 2 (GPR183)
J Biol Chem
Ligand modulation of the Epstein-Barr virus-induced seven-transmembrane receptor EBI2: identification of a potent and efficacious inverse agonist
J Biol Chem
Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR
Immunity
LXR-dependent gene expression is important for macrophage survival and the innate immune response
Cell
LXR signaling couples sterol metabolism to proliferation in the acquired immune response
Cell
Simian homologues of Epstein-Barr virus
Philos Trans R Soc Lond B Biol Sci
MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform
Nucleic Acids Res
New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0
Syst Biol
Epstein-Barr virus: 40 years on
Nat Rev Cancer
Fields Virology
Epstein-Barr virus entry
J Virol
Epstein-Barr virus enters B cells and epithelial cells by different routes
J Virol
Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus
Nat Med
The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output
PLoS Pathog
Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes
J Virol
Progress and problems in understanding and managing primary Epstein-Barr virus infections
Clin Microbiol Rev
The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination
PLoS Pathog
Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis
PLoS Biol
Clonal transformation of adult human leukocytes by Epstein-Barr virus
J Virol
Potential cellular functions of Epstein-Barr nuclear antigen 1 (EBNA1) of Epstein-Barr virus
Viruses
Epstein-Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2
Proc Natl Acad Sci U S A
EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors
J Clin Invest
Epstein-Barr virus: exploiting the immune system
Nat Rev Immunol
Epstein-Barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity
J Virol
Noncoding RNAs produced by oncogenic human herpesviruses
J Cell Physiol
Cited by (12)
Viral G protein–coupled receptors: Attractive targets for herpesvirus-associated diseases
2021, Pharmacological ReviewsHepatitis A and Other Viral Infections
2020, Liver Immunology: Principles and PracticeThe Epstein-Barr virus-encoded G protein-coupled receptor BILF1 upregulates ICAM-1 through a mechanism involving the NF-қB pathway
2020, Bioscience, Biotechnology and Biochemistry